Veterinary Cardiology Market Size & Share 2025 – 2034

Veterinary Cardiology Market Size

The global veterinary cardiology market was estimated at USD 2.7 billion in 2024. The market is expected to grow from USD 2.9 billion in 2025 to USD 6.1 billion in 2034, at a CAGR of 8.6%. The market is experiencing significant growth owing to the increasing prevalence of heart disease in companion animals and advancements in diagnostic and therapeutic solutions.

According to the American Veterinary Medical Association (AVMA), approximately 10% of dogs and 15% of cats develop heart disease during their lifetime, with mitral valve disease affecting nearly 75% of senior small-breed dogs. This growing numbers necessitate the requirement for better primary screening, advanced imaging modalities, and effective therapeutic approaches in veterinary medicine.
 

With better surgical outcomes and reduced surgical risks along with faster recovery times for patients, there is an increasing need for minimally invasive cardiology procedures such as balloon valvuloplasty for pulmonic stenosis, pacemaker implantation, and other catheter-based procedures. Also, newer medications such as pimobendan, ACE inhibitors, and beta-blockers have significantly improved the longevity of pets with cardiac disorders.
 

Further, the use of AI powered diagnostics and wearable cardiac monitoring devices is transforming early disease detection and long-term management strategies. Awareness among pet owners and the additional availability of specialized veterinary cardiology services is anticipated to fuel growth in the market. As more research is conducted in the field of veterinary cardiology, the market is expected to grow continuously over the forecast period.
 

The veterinary cardiology market involves diagnostic, therapeutic, and interventional solutions for heart diseases in animals. It includes advanced imaging, minimally invasive procedures, pharmacological treatments, and AI-driven monitoring technologies, aiming to enhance early detection, treatment precision, and overall cardiac health in companion and livestock animals.
 

Veterinary Cardiology Market Trends

• The veterinary cardiology industry is growing due to advancements in diagnostic and therapeutic solutions, as well as the increasing demand for specialized veterinary care and innovative technologies.
   
• The rising pet ownership plays a crucial role in driving demand for veterinary cardiology market. Nearly 70% of American families and around 50% of European families (166 million households) own a pet. This larger pet population leads to a higher incidence of cardiac conditions requiring medical intervention.
   
• Also, the gowning age-related heart diseases such as dilated cardiomyopathy (DCM) and congestive heart failure (CHF) have increased the need for new treatment alternatives.
   
• Another important factor contributing to the growth of the market is the increased spending on companion animal healthcare. According to the U.S. Bureau of Labor Statistics (BLS), American pet owners spent an average of USD 1,960 per year on their pets in 2023. The monthly pet ownership costs in 2024 are estimated at USD 143 for dogs and USD 90.5 for cats, indicating a need for specialized veterinary care.
   
• As a result of increased heart condition treatments, regulatory bodies such as FDA's Center for Veterinary Medicine (CVM) have granted more approvals for veterinary cardiac devices and medications. At the same time, AI diagnostics and wearable cardiac monitors are supporting improved detection and management of disease over time.
   
• Further, government and non-government initiatives are driving market expansion. In May 2024, the U.S. Department of Agriculture (USDA) allocated USD 22.2 million for disease prevention and early detection strategies which include cardiovascular research in veterinary medicine.
   
• Similarly, the National Institute of Food and Agriculture (NIFA) continues to invest in research focusing on cardiac disease prevention and novel treatment approaches. These efforts will likely lead to advances in veterinary cardiology, resulting in better clinical results and economic expansion of the industry.
   

Veterinary Cardiology Market Analysis

Based on the product type, the veterinary cardiology market is segmented into pharmaceutical and diagnostics. The pharmaceutical segment is further bifurcated into pimobendan, spironolactone and benazepril hydrochloride, and other pharmaceuticals The pharmaceutical segment dominated the market with USD 1.3 billion in 2021, USD 1.4 billion in 2022 and USD 1.5 billion in 2023.
 

• Innovations in veterinary medicine along with an upsurge in cases of heart diseases within companion animals, are the main drivers boosting growth of the pharmaceutical segment in veterinary cardiology market.
   
• The increase in pet life expectancy has also resulted in a higher prevalence of age-related cardiovascular diseases. This has increased demand for cardiac drugs to improve heart function, regulate blood pressure, and manage fluid retention.
   
• As per the American Veterinary Medical Association (AVMA), heart disease affects a substantial percentage of pets, with many requiring lifelong pharmaceutical managements. Also, the U.S. Bureau of Labor Statistics (BLS) reports that veterinary prescription medications are a key component of increasing pet healthcare expenditures.
   
• Further, the approval of new veterinary-specific cardiovascular drugs has expanded treatment options which have improved patient outcomes. Also, the increased investment in the development of combination drugs and novel formulation is expected to boost treatment outcome, thereby fostering the market.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on animal type, the veterinary cardiology market is divided into companion animals, and livestock animals. The companion animals segment is further classified into dogs, cats, and other companion animals. The companion animals segment accounted for a significant market share of 71.1% in 2024.
 

• The increasing adoption of pets, along with the rising prevalence of heart disease in pets, has driven growth of companion animals segment in the veterinary cardiology market. According to the American Veterinary Medical Association (AVMA), in 2024, there are 89.7 million dogs, and 73.8 million cats owned as pets in the U.S., emphasizing the rising demand for innovative veterinary solutions.
   
• Further, the increasing concern of pet owners regarding early disease recognition and better access to veterinary cardiologists is boosting the need for echocardiograms, electrocardiograms (ECG), diagnostic cardiac imaging, and advanced therapeutics.
   

Based on indication, the veterinary cardiology market is divided into congestive heart failure, myocardial (heart muscle) disease, arrhythmias, and other indications. The congestive heart failure segment dominated the market in 2024 and is expected to reach USD 2.6 billion by 2034.
 

• Congestive heart failure (CHF) is a significant concern in the veterinary cardiology market, affecting nearly 10% of all dogs and 30-60% of geriatric dogs, particularly small breeds such as Cavalier King Charles Spaniels and Doberman Pinschers. Among felines, hypertrophic cardiomyopathy (HCM) is the leading cause of CHF, impacting 15% of cats.
   
• The diagnosis and treatment of CHF has progressed with the introduction of ECG biomarker testing and other inventions in vet cardiology. Treatment options include pimobendan, diuretics, ACE inhibitors, and beta-blockers, which help manage symptoms and improve pet outcomes.
   
• Additionally, emerging technologies such as wearable cardiac monitors and telemedicine are enhancing long-term care for pets with heart disease.
   

Based on end use, the veterinary cardiology market is divided into veterinary hospitals and clinics, academic and research institutions, and other end users. The veterinary hospitals and clinics segment dominated the market in 2024 with USD 1.8 billion.   
 

• The veterinary hospitals and clinics segment is a key driver of the market, providing specialized diagnostic and treatment services for heart diseases in both companion and livestock animals.
   
• Facilities equipped with electrocardiogram (ECG) devices enable early detection of conditions such as mitral valve disease (MVD) and dilated cardiomyopathy (DCM).
   
• Veterinary clinics are also increasingly using newer therapeutics such as pimobendan, ACE inhibitors and beta blockers.
   
• There is also an increasing demand for improved accessibility and outcomes for cardiac care in veterinary hospitals and clinics using telemedicine, AI diagnostics, and other minimally invasive procedures.
   

The North America veterinary cardiology market held the largest market share of 41% in 2024 in the global market, and it is anticipated to expand at 8.5% CAGR over the forecast period. The U.S. market was valued at USD 812.3 million in 2021. The market size was valued at USD 872.8 million in 2022 and reached USD 939.6 million in 2023.
 

• The U.S. veterinary cardiology market is experiencing steady growth due to the rising prevalence of heart disease in pets, increased pet ownership, and advancements in diagnostic and therapeutic solutions.
   
• The increase in pet insurance coverage, which saw a growth of 20% in the year 2023, has supported spending in elevated veterinary care, leading to increased acceptance of specialized cardiac treatments.
   
• Technological innovations, including AI-driven diagnostics and wearable heart monitors, are further shaping the market.
   
• Further, the expansion of specialized veterinary hospitals and research facilities is accelerating the demand for advanced cardiology services across the U.S.
   

Europe veterinary cardiology market accounted for USD 758.3 million in 2024 and is anticipated to show considerable growth over the forecast period.
 

• The adoption of sophisticated veterinary healthcare solutions in Europe together with the proactive government policies aimed at improving the treatment of animals is driving the growth of the veterinary cardiology market.
   

• As per the European Pet Food Industry Federation (FEDIAF)’s survey conducted in 2024, Europe is home to 129 million cats and 106 million dogs, which boosts the need for specialized cardiac treatments. The figure is anticipated to rise exponentially. With pet owners seeking high-quality veterinary care, the demand for specialized cardiology services in Europe is expected to grow, making it a key player in Europe’s market.
   

• Germany, UK, and France are leading in specialized veterinary care, with expanding networks of referral hospitals and cardiology specialists, which is expected to accelerate the growth rate in this region.
   

The Asia Pacific veterinary cardiology market witnessed substantial growth of 9% during the analysis period.
 

• The Asia-Pacific market is expanding due to increasing pet adoption, improved veterinary infrastructure, and rising disposable incomes.
   

• Countries such as Japan, China, India and Australia are seeing a surge in demand for specialized cardiac care for animals. India is one of the emerging veterinary cardiology markets because of a growing pet population with over 31 million dogs and 3.7 million pet cats, which increases the demand for cardiac treatments.
   

• Also, growing awareness of animal health coupled with advancements in imaging and interventional cardiology is driving market growth.
   
• Further, increasing collaboration between veterinary institutions and pharmaceutical companies are fostering innovation, making Asia-Pacific a rapidly emerging market for veterinary cardiology services and treatments.
   

The Brazil veterinary cardiology market is experiencing robust growth in Latin America market.
 

• Brazil's market is growing due to increasing pet adoption, rising disposable income, and expanding veterinary infrastructure. With a large population of companion animals, including over 60 million dogs and 30 million cats. Therefore, increased awareness of pet heart diseases is leading to higher demand for preventive care and medications.
   
• Also, the growing presence of specialized veterinary hospitals further strengthens Brazil’s position in the Latin American veterinary cardiology sector.
   
• Government initiatives supporting veterinary healthcare advancements and the digitalization of veterinary services are fueling market expansion across the country.  
   

Veterinary Cardiology Market Share

The top 5 companies in the veterinary cardiology industry, such as Antech Diagnostics, Boehringer Ingelheim, Jurox, Ceva, and Merck, account for ~35% of the market share. These companies maintain their dominance through advancements in diagnostic imaging, cardiac pharmaceuticals, and AI-driven diagnostics, catering to the growing demand for specialized veterinary cardiology treatments.
 

Firms are expanding their offerings with ECG, X- ray solutions, patient-specific medications, and digital health tools to enhance early disease detection and treatment precision. Companies are investing in AI-powered analytics, wearable ECG technology, and minimally invasive surgical solutions, driving growth and competition in the veterinary cardiology sector.
 

Veterinary Cardiology Market Companies

Major players operating in the veterinary cardiology industry are:

• Antech Diagnostics
• Boehringer Ingelheim International
• Jurox
• Ceva
• Merck
• IDEXX
• General Electric Company
• FUJIFILM
• ESAOTE
• Medtronic
• Siemens Healthineers
• TriviumVet
• Zoetis
• Bionet America
   

Antech Diagnostics specializes in advanced veterinary diagnostic solutions, offering cardiac biomarker testing, echocardiography analysis, and AI-driven diagnostic tools. The company integrates machine learning algorithms with imaging data to enhance the early detection of heart diseases in pets.
 

Medtronic develops cutting-edge cardiac monitoring devices and implantable pacemakers for veterinary applications. The company’s miniaturized pacemakers and wearable ECG monitors help veterinarians track arrhythmias and heart failure progression in animals.
 

Boehringer Ingelheim specializes in pharmaceutical and biopharmaceutical solutions. Its VETMEDIN Solution (pimobendan oral solution) is the oral treatment for congestive heart failure in dogs, enhancing veterinary cardiology and remote patient care.
 

Veterinary Cardiology Industry News

• In March 2025, Fujifilm partnered with Us2.ai to offer AI-automated echocardiography analysis through their LISENDO 880 ultrasound system. This collaboration enhances diagnostic accuracy and efficiency for veterinary cardiologists and sonographers.
   
• In March 2025, Fujifilm signed a strategic collaboration agreement with Amazon Web Services (AWS) to enhance its veterinary cardiology solutions. This partnership aims to integrate cloud-based AI technologies, improving diagnostic accuracy and workflow efficiency for veterinary cardiac imaging and analysis.
   
• In November 2024, Boehringer Ingelheim launched VETMEDIN Solution, the first FDA-approved oral solution for managing congestive heart failure in dogs. This new liquid formulation offers a convenient treatment option for dogs with heart disease.  
   

The veterinary cardiology market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Pharmaceuticals        
  • Pimobendan
  • Spironolactone and benazepril hydrochloride
  • Other pharmaceuticals
• Diagnostics    
  • Physical exam
  • Chest X-rays
  • Electrocardiogram (ECG) 
  • Other diagnostics

Market, By Animal Type

• Companion animals
  • Dogs
  • Cats
  • Other companion animals
• Livestock animals
  • Cattle
  • Poultry
  • Other livestock animals

Market, By Indication

• Congestive heart failure
• Myocardial (heart muscle) disease
• Arrhythmias
• Other indications  

Market, By End Use

• Veterinary hospitals and clinics
• Academic and research institutions
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE